Casey McDonald

Some 20 states could have new right to try laws on the books by this time next year, though time will tell what kind of impact they'll have for patients or drug makers.

Fresh off Shire’s announcement to purchase NPS, CEO Dr. Flemming Ornskov sat down with PharmExec in San Francisco during the JP Morgan Healthcare Conference.

As we wrap up the week in San Francisco, here’s PharmExec's brief rundown of some of the top tweets of the week from JP Morgan and Biotech Showcase.

Pharm Exec’s annual report highlights the key scientific, commercial, and reputational trends shaping the industry in the year ahead.

PwC’s Health Research Institute (HRI) announced its top 10 health industry issues for 2015.

Not all companies are big, small companies are scared, and myths drive behavior, stated Kay Holcombe, Senior Vice President, Science Policy at Biotechnology Industry Organization (BIO).

Cleveland Clinic's Pick of Top 10 Advances for 2015.

Last week, the Access to Medicine Foundation released its 2014 Index rating the performance of companies in broadening access to medicines in low and middle-income countries.

CytRx announced on Tuesday that FDA gave notice of a partial clinical hold for trials for its oncology candidate aldoxorubicin.

A cool $2.6 billion is the going rate to develop and gain market approval for a drug, according to the recent study by the Tufts Center for the Study of Drug Development (CSDD).

Merck KGaA CEO Stefan Oschmann spoke last week in New York as he accepted the two-year role as president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the R&D industry’s global trade group based in Geneva.

“Don’t panic, this is the victory of the virus,” said Bernard Kouchner, co-founder of Medecins Sans Frontieres (Doctors Without Borders).

The Cleveland Clinic once again ended its Medical Innovation Summit with a list of 10 advances voted most likely to have a major impact on improving patient care in 2015.

Treatment Action Group (TAG) reaches a milestone in improving access to much-needed treatments for tuberculosis.

Last week’s Prix Galien Forum on global issues in life sciences was not without controversy.

An illustrious panel of investment professionals spoke optimistically on the orphan disease space in spite of concerns surrounding escalating drug prices in specialty pharmaceuticals.

Starting off this week’s Academy of Managed Care Pharmacy (AMCP) meeting in Boston, experts including patient access advocates, pharma and payer representatives came together for this year’s symposium entitled “Specialty Pharmacy and Patient Care: Are We at a Tipping Point?”

This week members of the Coalition for Healthcare Communication (CHC) met to discuss issues in healthcare communications and marketing like privacy and security, off-label advertising and the Sunshine Act along with an update on the overall DC environment.